Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hoepelman, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoepelman, I. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1996) 37, 871-880
© 1996 The British Society for Antimicrobial Chemotherapy

review-article

Current therapeutic approaches to cryptosporidiosis in immunocompromised patients

I. M. Hoepelman*

Department of Medicine, Division of Infectious Diseases and Eijkman Winkler Institute, University Hospital PO Box 85500, 3508 GA Utrecht, The Netherlands

Received 24 March 1995; returned 27 June 1995; accepted 18 August 1995

Cryptosporidium parvum is a protozon which can cause a severe debilitating disease in immunocompromised patients. Animal models show that cellular immunity is the most important factor protecting against the development of the disease, but patients with a humoral immune deficiency are also at risk. In HIV-infected patients there is a clear relationship between disease severity and CD4-cell counts. The development of insight into the pathogenesis and of new agents is hampered by the lack of an in-vitro culture system. Prevention is of utmost importance because of the difficulties of therapy and the severity of the clinical disease which can develop. Oocysts are highly resistant to the commonly used disinfectants. HIV-infected patients with cryptosporidiosis not on antiretroviral therapy should commence it. Non-specific therapy with anti-diarrhoeal agents should be instituted. If no effect is seen, therapy with paromomycin 500 mg qds for 2–3 weeks should be started, followed by maintenance therapy with 500 mg bid to prevent a relapse.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Burdese, V. Veglio, V. Consiglio, G. Soragna, E. Mezza, D. Bergamo, F. Tattoli, M. Rossetti, A. Jeantet, G. P. Segoloni, et al.
A dance teacher with kidney-pancreas transplant and diarrhoea: what is the cause?
Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1759 - 1761.
[Full Text] [PDF]

Home page
 Infect. Immun.Home page
C. Liu, V. Vigdorovich, V. Kapur, and M. S. Abrahamsen
A Random Survey of the Cryptosporidium parvum Genome
Infect. Immun., August 1, 1999; 67(8): 3960 - 3969.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.